BioSpace News Archive

Isotopia Molecular Imaging is pleased to announce that it has begun a collaboration with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biopharmaceutical company, for the supply of the medical radioisotope no-carrier-added 177Lu (n.c.a. 177Lu) to support clinical development of its targeted radiotherapeutic products

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2021 results on Wednesday, April 28, 2021 at 12 p.m. London time (7 a.m. Eastern Daylight Time).

For the fifth consecutive year, McKesson has received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR)

Owlet Baby Care Inc. announced today that a third-party study using data collected by its flagship product, the Owlet Smart Sock, identified that abnormally high heart rates – a condition known as a tachyarrhythmia – in infants are more common than existing clinical data has shown.

Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced the results of its March 24, 2021 shareholder meeting to approve the upcoming merger with StemoniX, Inc. (“StemoniX”).

Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the year ended December 31, 2020.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AztraZeneca AB and AstraZenca Pharmaceuticals LP (“AZ”) and Nektar Therapeutics (“Nektar”) have entered into a settlement and license agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories PVT. LTD.

PPJ Enterprise (Trading Symbol: OTC PINK:PPJE), a leader in Healthcare Reimbursement Cycle Expert for Complex Medical/Surgical Services and proprietary Automated Healthcare Practice Management Software, online Health Information Digital Systems and Medical Practice Information Management, is pleased to announce that the company signed new medical billing client.

The National Organization for Rare Disorders announced the findings of a new study that details the number of orphan products, generics and biosimilars available to treat rare diseases.

PCR Oncology and Deep Lens today announced a strategic partnership that will integrate artificial intelligence-based clinical trial screening and enrollment platform, VIPER™, into the PCR Oncology network.